TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36718176

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Peer coaching (PC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Practice facilitation (PF)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: EUC plus both PC and PF
Number of subjects: 69
Study: 36718400

Group type: EXPERIMENTAL
Intervention: Hypnotic Analgesia (HAS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: a-tDCS
Number of subjects: 18

Group type: COMPARATOR
Intervention: rest-testing
Number of subjects: 18
Study: 36718624

Group type: EXPERIMENTAL
Intervention: Senaparib (oral, 100 mg daily in 3-week cycles)
Number of subjects: 39
Study: 36718638

Group type: EXPERIMENTAL
Intervention: ARRY-371797 400 mg or 100 mg twice daily for 48 weeks
Number of subjects: 12
Study: 36718646

Group type: EXPERIMENTAL
Intervention: Near-Patient Testing (NPT)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Standard-of-Care Testing
Number of subjects: 656
Study: 36718763

Group type: EXPERIMENTAL
Intervention: Pi10 (standardized airway wall thickness)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 0
Study: 36718994

Group type: EXPERIMENTAL
Intervention: Classical conditioning with verbal suggestion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Verbal suggestion alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sham electrodes as placebo treatments
Number of subjects: 68

Group type: COMPARATOR
Intervention: Topical gels as placebo treatments
Number of subjects: 68
Study: 36719104

Group type: EXPERIMENTAL
Intervention: Triple therapy (esomeprazole 40 mg twice daily + amoxicillin 1000 mg three times daily + metronidazole 400 mg three times daily)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Dual therapy (esomeprazole 40 mg twice daily + amoxicillin 1000 mg three times daily)
Number of subjects: 268
Study: 36719158

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 36719160

Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study: 36719293

Group type: EXPERIMENTAL
Intervention: Vascular geometric model for noninvasive diagnosis of clinically significant portal hypertension (CSPH) using contrast-enhanced CT
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Vascular geometric model for noninvasive diagnosis of clinically significant portal hypertension (CSPH) using MRI
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Vascular geometric model for noninvasive diagnosis of clinically significant portal hypertension (CSPH) using CT
Number of subjects: 523

Group type: COMPARATOR
Intervention: Patients with CSPH (n=213)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Patients without CSPH (n=310)
Number of subjects: 523
Study: 36719367

Group type: EXPERIMENTAL
Intervention: MAPPWRQoL instrument
Number of subjects: 25

Group type: COMPARATOR
Intervention: WRQoL Scale
Number of subjects: 25
Study: 36719506

Group type: EXPERIMENTAL
Intervention: ICG-aPDT with an 810 nm diode laser
Number of subjects: 24

Group type: COMPARATOR
Intervention: FMUD (control)
Number of subjects: 24
Study: 36719566

Group type: EXPERIMENTAL
Intervention: Burosumab (0.8 mg/kg every 2 weeks for children; 1.0 mg/kg every 4 weeks for adults)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Burosumab self-administration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Burosumab administered by a healthcare professional (HCP)
Number of subjects: 24
Study: 36719704

Group type: EXPERIMENTAL
Intervention: Advanced triage implemented in the prospective phase (n=547)
Number of subjects: 1642

Group type: COMPARATOR
Intervention: Retrospective phase (n=1095)
Number of subjects: 1642
Study: 36719715

Group type: EXPERIMENTAL
Intervention: e-Vita HF platform (telemonitoring of blood pressure, pulse, and weight)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Personal health record usage
Number of subjects: 150
Study: 36719720

Group type: EXPERIMENTAL
Intervention: Amazon Alexa (digital screening)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Research coordinators (manual screening)
Number of subjects: 52
Study: 36719721

Group type: EXPERIMENTAL
Intervention: SiD decision aid
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control website
Number of subjects: 500
Study: 36719732

Group type: EXPERIMENTAL
Intervention: Malaysian Geriatric Patients' Hospital Foodservice Protocol (MYGERYFS)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 233
Study: 36719749

Group type: EXPERIMENTAL
Intervention: anti-LAG-3+anti-PD-1
Number of subjects: 40
Study: 36719784

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Number of subjects: 0
Study: 36719885

Group type: EXPERIMENTAL
Intervention: Pulmonary physiotherapy (PPT) - six sessions with breathing exercises and airway clearance techniques
Number of subjects: 40

Group type: COMPARATOR
Intervention: Basic care
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pulmonary physiotherapy (PPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pulmonary physiotherapy (PPT) and Basic care
Number of subjects: 40
Study: 36719886

Group type: EXPERIMENTAL
Intervention: Home-MCT+CR (n = 118)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual CR alone (n = 122)
Number of subjects: 240
Study: 36720083

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once-daily for 3 years
Number of subjects: 682

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 682
Study: 36720090

Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa plus venetoclax
Number of subjects: 23

Group type: COMPARATOR
Intervention: Eftozanermin alfa monotherapy
Number of subjects: 23
Study: 36720089

Group type: EXPERIMENTAL
Intervention: Complete severe acute respiratory syndrome coronavirus 2 vaccination course
Number of subjects: 613

Group type: COMPARATOR
Intervention: Prevaccination phase (February 27, 2020-November 30, 2020)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Alpha-Delta phase (December 1, 2020-December 14, 2021)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Omicron phase (December 15, 2021-January 31, 2022)
Number of subjects: 613
Study: 36720132

Group type: EXPERIMENTAL
Intervention: Extracorporeal CPR
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 160
Study: 36720133

Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa prophylaxis (50 IU/kg) for 52 weeks in group A
Number of subjects: 159

Group type: COMPARATOR
Intervention: Efanesoctocog alfa on-demand treatment for 26 weeks followed by prophylaxis for 26 weeks in group B
Number of subjects: 159
Study: 36720262

Group type: EXPERIMENTAL
Intervention: Multisearch Multilocation Task (MSML)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Snack Delay Task (SDT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Reversed Categorization Task (RevCat)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Executive function scores
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cognition and motor function
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Autism risk
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Executive function assessment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Executive function
Number of subjects: 97
Study: 36720290

Group type: EXPERIMENTAL
Intervention: Cold snare EMR (CS-EMR)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional EMR with thermal ablation (EMR-T)
Number of subjects: 104
Study: 36720425

Group type: EXPERIMENTAL
Intervention: Acute loading (one bout of resistance exercise - one-legged leg press)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no loading)
Number of subjects: 32
Study: 36720560

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg twice daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 204
Study: 36720570

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI (5-fluorouracil, oxaliplatin, and irinotecan) for four cycles as neoadjuvant chemotherapy (NAC)
Number of subjects: 0
Study: 36720576

Group type: EXPERIMENTAL
Intervention: 1.0 mg semaglutide once a week
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo once a week
Number of subjects: 104
Study: 36720731

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 10
Study: 36720768

Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAAs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 20
Study: 36720801

Group type: EXPERIMENTAL
Intervention: FFR-CT-guided strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QFR-guided strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (ICA and invasive pressure measurements)
Number of subjects: 0
Study: 36721130

Group type: EXPERIMENTAL
Intervention: PRESERFLO™ MicroShunt implantation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 124
Study: 36721135

Group type: EXPERIMENTAL
Intervention: Finnish Diabetes Risk Score (FINDRISC)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: HbA1c measurement
Number of subjects: 220
Study: 36721150

Group type: EXPERIMENTAL
Intervention: Deprescribing initiatives
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of interviews
Number of subjects: 28
Study: 36721157

Group type: EXPERIMENTAL
Intervention: L-GF injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (L-GF and Control)
Number of subjects: 60
Study: 36721174

Group type: EXPERIMENTAL
Intervention: HD201
Number of subjects: 502

Group type: COMPARATOR
Intervention: Referent trastuzumab
Number of subjects: 502
Study: 36721240

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) samples from individuals with NPC1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF CALB2 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF CHI3L1 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF CCL18 levels
Number of subjects: 0
Study: 36721372

Group type: EXPERIMENTAL
Intervention: Correct methods of analyzing accelerated aging detrended for age as the outcome and controlling for age as a covariate (n = 16; 32%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Correct methods of analyzing raw DNAm age as the outcome and controlling for age as a covariate (n = 5; 10%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Incorrect method of analyzing accelerated aging detrended for age as the outcome without controlling for age as a covariate (n = 29; 58%)
Number of subjects: 50
Study: 36721661

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36721920

Group type: EXPERIMENTAL
Intervention: 260 IU recombinant hCG (rhCG) daily injections for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cycle (no hCG priming)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Study cycle (hCG priming)
Number of subjects: 20
Study: 36721963

Group type: EXPERIMENTAL
Intervention: Inhaled siR-7-EM/KK-46 (3.7 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Inhaled siR-7-EM/KK-46 (11.1 mg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard etiotropic drug treatment (control group)
Number of subjects: 52
Study: 36722044

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP)
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 1070
Study: 36722133

Group type: EXPERIMENTAL
Intervention: sofosbuvir-velpatasvir
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sofosbuvir-velpatasvir-voxilaprevir
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DAAs (direct-acting antivirals)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma viremia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Second-phase plasma dynamics
Number of subjects: 10
Study: 36722147

Group type: EXPERIMENTAL
Intervention: RSVPreF3 (60 µg)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: RSVPreF3 (120 µg)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Infants of mothers vaccinated with RSVPreF3
Number of subjects: 213
Study: 36722187

Group type: EXPERIMENTAL
Intervention: Systematic screening strategy using high-sensitivity cardiac troponin T (hs-cTnT) assay measured before surgery, and at the 2nd and 3rd days after surgery
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Usual care strategy
Number of subjects: 1477
Study: 36722208

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 0
Study: 36722447

Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 21
Study: 36722463

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) parameters
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Mean heart rate
Number of subjects: 366
Study: 36722630

Group type: EXPERIMENTAL
Intervention: Intervention Group received three home visits by nurses one month after hospital discharge to provide stroke-related education and emotional support.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Group received the usual guidance from the health services.
Number of subjects: 48
Study: 36723286

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (n=27)
Number of subjects: 42

Group type: COMPARATOR
Intervention: COVID-19 infection (n=15)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of biopsy findings (2019-2021)
Number of subjects: 42
Study: 36723445

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36723678

Group type: EXPERIMENTAL
Intervention: Axi-cabtagene ciloleucel (axi-cel); chimeric antigen receptor T-cell therapy
Number of subjects: 229

Group type: COMPARATOR
Intervention: SCHOLAR-5 external control cohort
Number of subjects: 229
Study: 36723714

Group type: EXPERIMENTAL
Intervention: Supportive periodontal care (SPC)
Number of subjects: 108
Study: 36723801

Group type: EXPERIMENTAL
Intervention: BEAT Cancer (individualized exercise and group education)
Number of subjects: 222
Study: 36723880

Group type: EXPERIMENTAL
Intervention: Drop-in gamma probe
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rigid laparoscopic gamma probe (RLGP)
Number of subjects: 10
Study: 36723892

Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Number of subjects: 34

Group type: COMPARATOR
Intervention: 18F-FDG
Number of subjects: 34
Study: 36723911

Group type: EXPERIMENTAL
Intervention: Focal Irreversible Electroporation (IRE)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Extended Irreversible Electroporation (IRE)
Number of subjects: 106
Study: 36723913

Group type: EXPERIMENTAL
Intervention: Dupilumab once weekly
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Dupilumab every 2 weeks
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant TCS once weekly
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant TCS every 2 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 36723919

Group type: EXPERIMENTAL
Intervention: Personalized accelerated pacing
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study: 36723935

Group type: EXPERIMENTAL
Intervention: Tafamidis (80 mg or 20 mg)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 36723980

Group type: EXPERIMENTAL
Intervention: DIEP reconstruction
Number of subjects: 57

Group type: COMPARATOR
Intervention: Brava expansion and fat grafting
Number of subjects: 57
Study: 36723996

Group type: EXPERIMENTAL
Intervention: Continuous suture technique (CSG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interrupted suture technique (ISG)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study: 36724001

Group type: EXPERIMENTAL
Intervention: Single agent or combination therapy (inactive trials)
Number of subjects: 64

Group type: COMPARATOR
Intervention: SARC006 trial (upfront chemotherapy in chemotherapy naïve patients)
Number of subjects: 64
Study: 36724010

Group type: EXPERIMENTAL
Intervention: Digital health intervention (various functionalities including symptom diary, sleep time setting, alcohol tracker, exercise day setting, thought diary, goal setter)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Digital health intervention
Number of subjects: 50
Study: 36724067

Group type: EXPERIMENTAL
Intervention: Vascular-targeted photodynamic therapy with WST-11 at a dose of 200 mW/cm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vascular-targeted photodynamic therapy with WST-11
Number of subjects: 19
Study: 36724109

Group type: EXPERIMENTAL
Intervention: Zuranolone, dosage and duration not available
Number of subjects: 0
Study: 36724181

Group type: EXPERIMENTAL
Intervention: Satralizumab
Number of subjects: 111
Study: 36724193

Group type: EXPERIMENTAL
Intervention: Vitamin C 500mg twice daily for 8 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 180
Study: 36724311

Group type: EXPERIMENTAL
Intervention: Usual insulin pump (UP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Automated insulin delivery (AID) (MiniMed™ 780G)
Number of subjects: 10
Study: 36724328

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 725

Group type: COMPARATOR
Intervention: Ex situ kidney hypothermic machine perfusion
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Combination therapy (hypothermia + machine perfusion)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Hypothermia vs Machine Perfusion
Number of subjects: 725

Group type: COMPARATOR
Intervention: Hypothermia vs Combination Therapy
Number of subjects: 725

Group type: COMPARATOR
Intervention: Combination Therapy vs Machine Perfusion
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Graft survival at 1 year
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 725
Study: 36724401

Group type: EXPERIMENTAL
Intervention: High perceived efficacy in patient-physician interaction
Number of subjects: 93

Group type: COMPARATOR
Intervention: Low perceived efficacy in patient-physician interaction
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Smartwatch prescription for AF
Number of subjects: 93
Study: 36724434

Group type: EXPERIMENTAL
Intervention: Double-dosed LPV/r (ratio 8:2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Semisuperboosted LPV/r (adding a ritonavir 100 mg crushed tablet)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control arm (no rifampicin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rifampicin co-treatment
Number of subjects: 16
Study: 36724515

Group type: EXPERIMENTAL
Intervention: Olutasidenib (FT-2102) 150 mg twice daily
Number of subjects: 153
Study: 36724589

Group type: EXPERIMENTAL
Intervention: Constant Exercise (CE)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intermittent Exercise (IE)
Number of subjects: 16
Study: 36724759

Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery of autologous cerebrospinal fluid (CSF) at a convective rate of 5 µL/min with a maximum volume of infusion of 500 mL
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery of autologous cerebrospinal fluid (CSF)
Number of subjects: 4
Study: 36724791

Group type: EXPERIMENTAL
Intervention: Less baseline time in sedentary behavior (SB)
Number of subjects: 205
Study: 36724939

Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 360

Group type: COMPARATOR
Intervention: MCV4-DT
Number of subjects: 360
Study: 36725084

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (Cohort A)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (Cohort A1)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (Cohorts A and A1)
Number of subjects: 589
Study: 36725090

Group type: EXPERIMENTAL
Intervention: CDED+antibiotics (azithromycin 7.5 mg/kg and metronidazole 20 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CDED+PEN alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CDED+antibiotics
Number of subjects: 20
Study: 36725099

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 595
Study: 36725102

Group type: EXPERIMENTAL
Intervention: Social media and smartphone use
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Anxiety, depression, sleep disturbance, loneliness, and bullying
Number of subjects: 600
Study: 36725117

Group type: EXPERIMENTAL
Intervention: GPRC5D-targeted CAR T cells (OriCAR-017) administered as a single dose of intravenous 1 × 10^6 cells/kg
Number of subjects: 13
Study: 36725118

Group type: EXPERIMENTAL
Intervention: Non-Hispanic White patients
Number of subjects: 21952

Group type: EXPERIMENTAL
Intervention: Hispanic patients
Number of subjects: 21952

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Black patients
Number of subjects: 21952

Group type: EXPERIMENTAL
Intervention: Non-Hispanic Asian patients
Number of subjects: 21952

Group type: EXPERIMENTAL
Intervention: Non-Hispanic other patients
Number of subjects: 21952
Study: 36725171

Group type: EXPERIMENTAL
Intervention: PASCAL system
Number of subjects: 98
Study: 36725361

Group type: EXPERIMENTAL
Intervention: First Pass Effect (FPE)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Multiple Pass Effect (MPE)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Incomplete Recanalization (ICR)
Number of subjects: 279
Study: 36725431

Group type: EXPERIMENTAL
Intervention: BNT162b2 (heterologous booster)
Number of subjects: 305

Group type: COMPARATOR
Intervention: BBIBP (homologous booster)
Number of subjects: 305
Study: 36725433

Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP vaccination
Number of subjects: 32
Study: 36725768

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 166
Study: 36725836

Group type: EXPERIMENTAL
Intervention: Camrelizumab
Number of subjects: 0